Loading…
Loading…
Issued jointly by Huangpu District's Science and Technology Commission and Investment Promotion Office (not a national or even full-municipal instrument — Huangpu is one of Shanghai's 16 districts, the central business/financial district), the measure is a district-level supply-side subsidy stack for biopharma R&D and clinical translation. It layers four instrument types:
undertaking national science-and-technology major projects in cell & gene therapy, mRNA, synthetic biology, regenerative medicine and digital medicine.
(capped CNY 2m) for professional biopharma labs and translational result-conversion platforms.
CNY 1m) for enterprises using the district's translational-medicine national major science infrastructure (the Shanghai Jiao Tong-linked facility referenced in the policy).
Phase I trials receive up to CNY 2m and Phase II up to CNY 5m, with a CNY 50m/year per-entity cap — the largest single line item in the measure.
agglomeration-effective biopharma industrial-park operators.
Funding retroactively covers relevant CNY-support activity from 1 January 2025 through the measure's implementation date.
administrative rung below the Shanghai municipal government's own biomanufacturing-inclusive advanced-manufacturing plan (2025-12-30-shanghai-advanced-manufacturing-transformation-action-plan) and beneath national biomedical-technology rule-making (State Council Order 818 on biomedical new technologies) — another data point on how granular China's sub-national industrial-policy layering has become in strategic-emerging-industry sectors.
entity, the Phase I/II milestone-grant cap dwarfs the R&D and platform grants (CNY 1-2m) — the policy is weighted toward de-risking late-stage domestic drug development and commercialization rather than early research, consistent with Beijing's broader push to convert lab-stage biotech IP into approved, revenue-generating domestic drugs.
when assessing cumulative Chinese state aid to biopharma for EU Foreign Subsidies Regulation or Section 301-style overcapacity arguments, alongside the municipal and national instruments above.
an aggregate district appropriation — actual fiscal-year disbursement would need Huangpu District Finance Bureau budget execution reports.
disclosed yet; watch Huangpu district government announcements for the first grant-recipient lists once the measure takes effect.